| Literature DB >> 33972565 |
Glenn A Marsh1, Alexander J McAuley1, Gough G Au1, Sarah Riddell1, Daniel Layton1, Nagendrakumar B Singanallur1, Rachel Layton1, Jean Payne1, Peter A Durr1, Hannah Bender1, Jennifer A Barr1, John Bingham1, Victoria Boyd1, Sheree Brown1, Matthew P Bruce1, Kathie Burkett1, Teresa Eastwood1, Sarah Edwards1, Tamara Gough1, Kim Halpin1, Jenni Harper1, Clare Holmes1, William S J Horman1, Petrus Jansen van Vuren1, Suzanne Lowther1, Kate Maynard1, Kristen D McAuley1, Matthew J Neave1, Timothy Poole1, Christina Rootes1, Brenton Rowe1, Elisha Soldani1, Vittoria Stevens1, Cameron R Stewart1, Willy W Suen1, Mary Tachedjian1, Shawn Todd1, Lee Trinidad1, Duane Walter1, Naomi Watson1, Trevor W Drew1, Sarah C Gilbert2, Teresa Lambe2, S S Vasan3,4.
Abstract
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.Entities:
Year: 2021 PMID： 33972565 DOI： 10.1038/s41541-021-00315-6
Source DB: PubMed Journal: NPJ Vaccines ISSN： 2059-0105 Impact factor: 7.344